Galapagos CEO Paul Stoffels bets €225M on a new CAR-T strategy for the long suffering biotech – Endpoints News

Most food allergy care involves avoidance — checking ingredient labels, no peanut tables in schools, and so on. However, that paradigm has been shifting with oral immunotherapies, or OITs for short, in which patients purposely eat a bit of their allergen in the form of a modified protein in hopes of training their immune system to tolerate it.

Alladapt Immunotherapeutics is creating a single OIT for all major IgE-mediated food allergies — “what we call the big nine,” as Alladapt CEO Ashley Dombkowski said — for milk, eggs, wheat, fish, shellfish, peanuts, tree nuts, soy and sesame. Now, the biotech has $119 million to push that drug through clinical trials.

Leave a Comment